Company Information
CIN
Status
Date of Incorporation
16 May 2005
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2017
Last Annual Meeting
21 August 2017
Paid Up Capital
222,980
Authorised Capital
500,000
Directors
Bharat Vinod Daftary
Director/Designated Partner
over 2 years ago
over 2 years ago
Gautam Vinod Daftary
Director/Designated Partner
over 2 years ago
over 2 years ago
Zubin Meherwan Merchant
Additional Director
over 8 years ago
over 8 years ago
Rajesh Premchand Agarwal
Director
about 11 years ago
about 11 years ago
Vikram Himatlal Parekh
Director
about 11 years ago
about 11 years ago
Girish Bakre
Director
over 12 years ago
over 12 years ago
Raj Nautam Parekh
Director
about 14 years ago
about 14 years ago
Past Directors
Kavita Khanna Vinod
Additional Director
about 12 years ago
about 12 years ago
Patents
The invention relates to a method for isolation, purification and industrial scale expansion of canine adipose tissue derived mesenchymal stem cells (MSCs). The invention also relates to a method for treating and a therapeutic product for treating osteoarthritis, spinal cord injury, atopic dermatitis, dilated cardio...
The invention relates to a method for isolation, purification and industrial scale expansion of equine adipose tissue derived mesenchymal stem cells (MSCs). The invention also relates to a method for treating and a therapeutic product for treating tendon injury, ligament injury, osteoarthritis and exercise induced p...
The invention relates to a method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells (MSCs). The invention also relates to a method for treating and a therapeutic product for treating type-1 diabetes mellitus, critical limb ischemia, multiple sclerosis, ...
The invention relates to an intra-dermally, sub-dermally or topically administrable growth factor concentrate derived from approximately 500 x106 to 1500 x106 human platelets per ml for treating hair loss. The concentrate comprises approximately 800 to 1200 pg/ml of Epidermal growth factor (EGF), 20 to SO pg/ml of V...
The invention relates to an intra-articularly administrable growth factor concentrate derived from approximately 250 x106 to 5000 x106 human platelets per ml for treating tendinopathies. The concentrate comprises approximately 900 to 2000 pg/ml of Epidermal growth factor (EGF), 30 to 300 pg/ml of Vascular Endothelia...
The invention relates to a method of preparing an intra-dermally, intra-articularly, sub-dermally or topically administrable growth factor concentrate derived from human platelets. The method comprises the steps of suspending human platelets in multiple electrolyte isotonic solution; snap-freezing the suspension; th...
The invention relates to an intra-dermally, sub-dermally or topically administrable growth factor concentrate derived from approximately 250 x 10 to 5000 x lO6 human platelets per ml for treating facial wrinkles. The concentrate comprises approximately 900 to 2000 pg/ml of Epidermal growth factor (EGF), 30 to 300 pg...
The invention relates to an intra-dermally, sub-dermally or topically administrable growth factor concentrate derived from approximately 250 xl06 to 5000 x106 human platelets per ml for treating periorbital hyperpigmentation. The concentrate comprises approximately 900 to 2000 pg/ml of Epidermal growth factor (EGF),...
Registered Trademarks
[Class : 42] Research And, Development; Scientific Research And Development Services For Medical Purposes; Pharmaceutical Research And Development; Development Of Stem Cell Expansion Methods; Development Of Regenerative Therapeutic And Pharmaceutical Products
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
[Class : 44] Medical Services; Veterinary Services; Stem Cell Therapy
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
[Class : 42] Research And, Development; Scientific Research And Development Services For Medical Purposes; Pharmaceutical Research And Development; Development Of Stem Cell Expansion Methods; Development Of Regenerative Therapeutic And Pharmaceutical Products
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
View +8 more Brands for Kasiak Research Private Limited Cn.
Charges
08 December 2011
Bank Of Baroda
4 Crore
08 December 2011
Bank Of Baroda
0
08 December 2011
Bank Of Baroda
0
08 December 2011
Bank Of Baroda
0
Documents
Form INC-28-04102018-signed
Optional Attachment-(2)-02102018
Copy of court order or NCLT or CLB or order by any other competent authority.-02102018
Optional Attachment-(1)-02102018
Optional Attachment-(3)-02102018
Form MGT-14-17052018_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-17052018
Consolidated Financial statements duly authenticated as per section 134 (Including Boards report, auditors report and other docu-19122017
Supplementary or Test audit report under section 143-19122017
Form AOC - 4 CFS-19122017_signed
Statement of Subsidiaries as per section 129 - Form AOC-1-18122017
Directors report as per section 134(3)-18122017
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-18122017
Form AOC-4-18122017_signed
Form ADT-1-04122017_signed
Consolidated Financial statements duly authenticated as per section 134 (Including Boards report, auditors report and other docu-04122017
Supplementary or Test audit report under section 143-04122017
Form AOC - 4 CFS-04122017_signed
Copy of written consent given by auditor-01122017
Copy of the intimation sent by company-01122017
Copy of resolution passed by the company-01122017
Form AOC-4-21112017_signed
Directors report as per section 134(3)-18112017
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-18112017
Statement of Subsidiaries as per section 129 - Form AOC-1-18112017
List of share holders, debenture holders;-15112017
Form MGT-7-15112017_signed
List of share holders, debenture holders;-14112017
